Leukemia in Rochester (NY). A 17-year experience with an analysis of the role of cooperative group (ECOG) participation
- PMID: 3902204
- DOI: 10.1002/1097-0142(19851101)56:9<2161::aid-cncr2820560904>3.0.co;2-m
Leukemia in Rochester (NY). A 17-year experience with an analysis of the role of cooperative group (ECOG) participation
Abstract
Every adult acute nonlymphocytic leukemia patient in Rochester, New York seen from January 1975 to January 1982 was studied. Fifty percent of the patients did not receive combination chemotherapy. Among those who did, there was a significant selection bias toward placing patients with better prognostic features on protocol. Protocol patients were also treated with higher doses of chemotherapy than nonprotocol patients. However, these factors did not completely explain the significantly better complete response (CR) rate and survival among protocol patients. Eastern Cooperative Oncology Group (ECOG) participation remained an independent variable associated with a better outcome. An improvement in CR rate was seen during the 7-year period studied as compared to that seen between 1965 and 1974. The study provided evidence that the availability and use of ECOG protocols was a positive factor in the improvement of leukemia treatment in Rochester.
Similar articles
-
Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly.J Clin Oncol. 1984 Aug;2(8):865-70. doi: 10.1200/JCO.1984.2.8.865. J Clin Oncol. 1984. PMID: 6379120 Clinical Trial.
-
Financial analysis of patients with newly diagnosed acute myelogenous leukemia on protocol or standard therapy.Cancer. 2002 Sep 1;95(5):1064-70. doi: 10.1002/cncr.10805. Cancer. 2002. PMID: 12209692
-
Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia.Cancer Treat Rep. 1987 Feb;71(2):137-40. Cancer Treat Rep. 1987. PMID: 3802110
-
Clinical trials of adult acute nonlymphocytic leukemia: evidence of progress.Cancer Treat Rev. 1985 Jun;12(2):133-43. doi: 10.1016/0305-7372(85)90004-0. Cancer Treat Rev. 1985. PMID: 3902216 Review. No abstract available.
-
[State of the art of chemotherapy for adult acute leukemia in Japan].Gan To Kagaku Ryoho. 1993 Dec;20(16):2478-82. Gan To Kagaku Ryoho. 1993. PMID: 8279845 Review. Japanese.
Cited by
-
Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden.Br J Cancer. 2000 Apr;82(8):1387-92. doi: 10.1054/bjoc.1999.1123. Br J Cancer. 2000. PMID: 10780515 Free PMC article.
-
Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate.Cochrane Database Syst Rev. 2008 Jul 16;2008(3):MR000009. doi: 10.1002/14651858.MR000009.pub4. Cochrane Database Syst Rev. 2008. PMID: 18677782 Free PMC article. Review.
-
The breast cancer research scandal: addressing the issues.CMAJ. 1995 Apr 15;152(8):1195-7. CMAJ. 1995. PMID: 7736369 Free PMC article.
-
Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma.Br J Cancer. 1994 Dec;70(6):1203-10. doi: 10.1038/bjc.1994.474. Br J Cancer. 1994. PMID: 7981078 Free PMC article. Clinical Trial.
-
Barriers and facilitators for clinical trial participation among diverse Asian patients with breast cancer: a qualitative study.BMC Womens Health. 2016 Jul 22;16:43. doi: 10.1186/s12905-016-0319-1. BMC Womens Health. 2016. PMID: 27449505 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Medical